Sarepta's NDA will not be reviewed until 2016

The Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee will not review Sarepta Therapeutics Inc.'s (Nasdaq: SRPT) New Drug Application for the Duchenne muscular dystrophy treatment eteplirsen until January 22, 2016 sending the stock price plummeting $3.88 to close at $29.06.